RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
International Stem Cell Stock

International Stem Cell ROCE 2024

International Stem Cell ROCE

-5.87

Ticker

ISCO

ISIN

US4603782016

In 2024, International Stem Cell's return on capital employed (ROCE) was -5.87, a -805.35% increase from the 0.83 ROCE in the previous year.

International Stem Cell Aktienanalyse

What does International Stem Cell do?

International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling International Stem Cell's Return on Capital Employed (ROCE)

International Stem Cell's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing International Stem Cell's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

International Stem Cell's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in International Stem Cell’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about International Stem Cell stock

What is the ROCE (Return on Capital Employed) of International Stem Cell this year?

The ROCE of International Stem Cell is -5.87 undefined this year.

How has the ROCE (Return on Capital Employed) of International Stem Cell developed compared to the previous year?

The ROCE of International Stem Cell has increased by -805.35% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of International Stem Cell?

A high Return on Capital Employed (ROCE) indicates that International Stem Cell has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of International Stem Cell?

A low ROCE (Return on Capital Employed) can indicate that International Stem Cell has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from International Stem Cell impact the company?

An increase in the ROCE of International Stem Cell can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of International Stem Cell affect the company?

A decrease in ROCE of International Stem Cell can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of International Stem Cell?

Some factors that can affect International Stem Cell's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of International Stem Cell so important for investors?

The ROCE of International Stem Cell is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can International Stem Cell take to improve the ROCE?

To improve the ROCE, International Stem Cell can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does International Stem Cell pay?

Over the past 12 months, International Stem Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, International Stem Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of International Stem Cell?

The current dividend yield of International Stem Cell is .

When does International Stem Cell pay dividends?

International Stem Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of International Stem Cell?

International Stem Cell paid dividends every year for the past 0 years.

What is the dividend of International Stem Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is International Stem Cell located?

International Stem Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von International Stem Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of International Stem Cell from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did International Stem Cell pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of International Stem Cell in the year 2023?

In the year 2023, International Stem Cell distributed 0 USD as dividends.

In which currency does International Stem Cell pay out the dividend?

The dividends of International Stem Cell are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von International Stem Cell

Our stock analysis for International Stem Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of International Stem Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.